Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone/Dapagliflozin in Chronic Kidney Disease and Albuminuria
NCT06350123Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of balcinrenone in chronic kidney disease (CKD), albuminuria, sponsored by AstraZeneca. Started May 2024; status: completed.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)albuminuria
Beyond the preview
Go deeper on NCT06350123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350123.